Literature DB >> 9797205

Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.

I González1, M Georgiou, F Alcaide, D Balas, J Liñares, A G de la Campa.   

Abstract

The nucleotide sequences of the quinolone resistance-determining regions (QRDRs) of the parC and gyrA genes from seven ciprofloxacin-resistant (Cpr) isolates of viridans group streptococci (two high-level Cpr Streptococcus oralis and five low-level Cpr Streptococcus mitis isolates) were determined and compared with those obtained from susceptible isolates. The nucleotide sequences of the QRDRs of the parE and gyrB genes from the five low-level Cpr S. mitis isolates and from the NCTC 12261 type strain were also analyzed. Four of these low-level Cpr isolates had changes affecting the subunits of DNA topoisomerase IV: three in Ser-79 (to Phe or Ile) of ParC and one in ParE at a position not previously described to be involved in quinolone resistance (Pro-424). One isolate did not show any mutation. The two high-level Cpr S. oralis isolates showed mutations affecting equivalent residue positions of ParC and GyrA, namely, Ser-79 to Phe and Ser-81 to Phe or Tyr, respectively. The parC mutations were able to transform Streptococcus pneumoniae to ciprofloxacin resistance, while the gyrA mutations transformed S. pneumoniae only when mutations in parC were present. These results suggest that DNA topoisomerase IV is a primary target of ciprofloxacin in viridans group streptococci, DNA gyrase being a secondary target.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797205      PMCID: PMC105945     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae.

Authors:  D Balas; E Fernández-Moreira; A G De La Campa
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

2.  In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.

Authors:  F Alcaide; J Carratala; J Liñares; F Gudiol; R Martin
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

Authors:  R Muñoz; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.

Authors:  X S Pan; L M Fisher
Journal:  J Bacteriol       Date:  1996-07       Impact factor: 3.490

6.  Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.

Authors:  D M Breines; S Ouabdesselam; E Y Ng; J Tankovic; S Shah; C J Soussy; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

7.  Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.

Authors:  J Tankovic; B Perichon; J Duval; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.

Authors:  M Georgiou; R Muñoz; F Román; R Cantón; R Gómez-Lus; J Campos; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

10.  Topoisomerase IV is a target of quinolones in Escherichia coli.

Authors:  A B Khodursky; E L Zechiedrich; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more
  39 in total

1.  In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.

Authors:  J C de Azavedo; L Trpeski; S Pong-Porter; S Matsumura; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  D J Bast; J C de Azavedo; T Y Tam; L Kilburn; C Duncan; L A Mandell; R J Davidson; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

3.  Levofloxacin-resistant Streptococcus pneumoniae: second look.

Authors:  C Thornsberry; J A Karlowsky; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 4.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

5.  Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Josefina Liñares; Fe Tubau; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

6.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

7.  Clinical Isolates of the Spain14-5 clone of Streptococcus pneumoniae carry a recombinant rpoB gene.

Authors:  M J Ferrándiz; E Pérez-Trallero; J M Marimón; A G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  First characterization of fluoroquinolone resistance in Streptococcus suis.

Authors:  Jose Antonio Escudero; Alvaro San Millan; Ana Catalan; Adela G de la Campa; Estefania Rivero; Gema Lopez; Lucas Dominguez; Miguel Angel Moreno; Bruno Gonzalez-Zorn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

9.  Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.

Authors:  Hsiu-Mei Wu; Rajendra Prasad Janapatla; Yueh-Ren Ho; Kuei-Hsiang Hung; Chi-Wen Wu; Jing-Jou Yan; Jiunn-Jong Wu
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.